acth-(4-7)--pro-gly-pro- and Psoriasis

It was studied the possibility of correcting lipid metabolism in patients with psoriasis and concomitant metabolic syndrome (MS) by using additional treatment with semax. In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days. It was found that the inclusion of semax in complex treatment of patients with psoriasis complicated by metabolic syndrome led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment, which did not produce any statistically significant effect on the levels of total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol in the blood serum.

Topics: Administration, Intranasal; Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Neuroprotective Agents; Peptide Fragments; Prospective Studies; Psoriasis; Triglycerides